Core Viewpoint - WuXi AppTec (02268) has shown a strong performance with a stock price increase of 4.89% to HKD 70.8, amid a broader recovery in the healthcare sector, despite a recent pullback in the pharmaceutical market [1] Group 1: Market Performance - WuXi AppTec's stock rose over 5% in the morning session, with a trading volume of HKD 145 million [1] - The MSCI China Healthcare Index has increased by 59.5% year-to-date, outperforming the MSCI China Index by 24% [1] Group 2: Analyst Insights - CCB International's latest report highlights that despite a 10% pullback in the pharmaceutical sector since early October, undervalued pharmaceutical companies like WuXi AppTec remain attractive [1] - The firm anticipates a recovery in capital market financing activities and an expansion in the overseas trading scale of innovative drugs, alongside a rebound in domestic R&D demand for innovative drugs [1] Group 3: Company Performance and Prospects - Goldman Sachs reports that WuXi AppTec's order momentum remains strong, particularly from U.S. clients, with a target of 45% year-on-year revenue growth on track [1] - The company is actively negotiating contracts for its Singapore facility, expecting to sign several agreements by year-end, although revenue contributions from this facility will be limited until 2027 due to capacity expansion timelines [1]